EAM
PBYI icon

Eagle Asset Management’s Puma Biotechnology PBYI Stock Holding History

Eagle Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-237,710
Closed -$14.1M – 631
2018
Q2 		$14.1M Sell
237,710
-61,533
-21% -$3.57M 0.08% 277
2018
Q1 		$20.4M Buy
299,243
+1,623
+0.5% +$122K 0.11% 237
2017
Q4 		$28.9M Buy
+297,620
New +$33.3M 0.16% 208
2015
Q2 		– Sell
-222,100
Closed -$52.4M – 664
2015
Q1 		$52.4M Sell
222,100
-2,769
-1% -$592K 0.3% 124
2014
Q4 		$42.6M Sell
224,869
-2,601
-1% -$577K 0.24% 146
2014
Q3 		$54.3M Sell
227,470
-248,298
-52% -$51M 0.31% 109
2014
Q2 		$31.4M Buy
475,768
+149,129
+46% +$10.6M 0.17% 178
2014
Q1 		$34M Buy
+326,639
New +$38.4M 0.19% 177

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Eagle Asset Management's PBYI Position: Q3 2018 in Review

Eagle Asset Management sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 237,710 shares — an estimated $14.1M sold.

Eagle Asset Management first reported a position in PBYI in Q1 2014 and held it in 8 quarters. The position peaked at $54.3M in Q3 2014. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

  • Eagle Asset Management reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
  • Eagle Asset Management sold 237,710 Puma Biotechnology shares in Q3 2018, an estimated $14.1M.
  • Eagle Asset Management first reported a position in Puma Biotechnology in Q1 2014 and held it in 8 quarters.
  • Eagle Asset Management's Puma Biotechnology position peaked at $54.3M in Q3 2014.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Eagle Asset Management's 13F filing for Q3 2018, filed 8 Nov 2018.